Prevention of Hepatic Encephalopathy With Mobile Application Based Lactulose Titration


About this study

The purpose of this study is to determine if a mobile application used to label stools according to the Bristol Stool Scale can safely assist subjects with lactulose titration and lead to decreased rates of hepatic encephalopathy. Additionally, to assess patient willingness to interact with mobile application in taking pictures of bowel movements.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients over the age of 18 years.
  • Ability to provide written, informed consent.
  • Currently taking lactulose daily for prevention of hepatic encephalopathy.

Exclusion Criteria:

  • Recent change in dosing of opioid medication.
  • Previous Colorectal Surgery.
  • Active diarrheal illness.
  • Lack of smartphone or other smart device at home.

Eligibility last updated 7/8/22. Questions regarding updates should be directed to the study team contact.


Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Douglas Simonetto, M.D.

Closed for enrollment

Contact information:

Daniel Penrice M.D.

More information


Publications are currently not available

Mayo Clinic Footer